services banner

Avance Workshops

2014 - April 7/8 - License Contract and Company Valuation - Basel

Avance Newsletter

Newsletter January 2014

  • Correlated Milestones

Newsletter November 2013

  • Valuation at cost

Newsletter September 2013

  • A statistical view on success rates

Newsletter April 2013

  • Comparables

Newsletter August 2012

  • Evolution of valuation

Newsletter February 2012

  • Sensitivities in valuation

Newsletter October 2011

  • High finance in biotech?

Newsletter September 2011

  • Phase 2a and 2b transition probabilities

Newsletter August 2011

  • How to value option agreements?

Newsletter May 2011

  • Early-stage project valuation myths

Newsletter February 2011

  • NPV vs. rNPV
  • Deal Analysis: CellGenesys - Takeda

Newsletter January 2011

  • Survey on discount rates in biotech
  • Should we discount by project or by company? (continued)

Newsletter December 2010

  • Should we discount by project or by company?
  • Deal Analysis: Adnexus-BMS

Newsletter August 2010

  • Black's risk-free discounting rule
  • Deal Analysis: Ardea-Bayer

Newsletter May 2010

  • How Biotech Stocks Behave
  • Deal Analysis: Plexxikon - Roche

Newsletter March 2010

  • Why drug prices must be high
  • Deal Analysis of Celldex-Pfizer

Newsletter January 2010

  • Staged Take-Overs: New deal structure on the rise
  • Risk Premium
  • Deal Analysis of KyowaKirin-Amgen

Newsletter November 2009

  • Biotech Success Rates: NCEs vs. Biologicals
  • Real Options: Dos and Don'ts

Newsletter July 2009

  • Optimal Portfolio Structure
  • Employee Stock Option Plans

Newsletter March 2009

  • Success Rates in Biotech: Going the Wrong Way
  • Early-Stage Licensing: How to Determine Sublicensing Terms

Newsletter December 2008

  • Avance Survey on Financial Crisis and Impact on Biotech and Pharma Companies
  • Funny Valuations

Newsletter September 2008

  • Why are royalties up-tiered?
  • Arbitrary Terminal Value

Newsletter July 2008

  • P/E Ratio for Biotech Valuation.
  • Multi-indication Deals - How to Value Them.

Newsletter May 2008

  • Co-Development Deals - How to Determine a Fair Share?
  • Biotech Taxes - Effects on Valuation?

Newsletter March 2008

  • Reading Deals - How to Interpret Licensing Deals
  • No-Dilutive Financing Alternatives

Newsletter January 2008

  • Forecasting Sales - Competition Scenarios
  • Discount Rates in Pharma and Biotech

Newsletter December 2007

  • Discovery & Preclinical Deals: What's realistic?
  • The US$ 1 bio drug. A fairytale

 

 





Home | About Avance | Services | ri:val | Publications | Book | Contact | Disclaimer-Terms